Los puntos clave no están disponibles para este artículo en este momento.
CTLA4 blockade with tremelimumab diversifies the peripheral T-cell pool, representing a pharmacodynamic effect of how this class of antibodies modulates the human immune system.
Robert et al. (Sat,) studied this question.